IL-10 muteins and fusion proteins thereof
AssigneeAmgen Inc.
InventorsHailing Hsu, Ian Foltz, Marissa Mock, Victor Mitch Luna, Ming Zhang, Sharon Lynn Wannberg, Gamze Ozlem Camdere Tapia, Timothy Patrick Riley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, to muteins of IL-10 that are stable as monomers, antigen binding proteins that bind to TREM-1, and antigen binding proteins comprising IL-10 muteins and antigen binding moieties, e.g., anti-TREM-1 antibodies, and compositions thereof. The disclosure also provides methods of treating inflammatory disease, such as inflammatory bowel disease or ulcerative colitis, using the compositions.
Claims6
A human interleukin-10 (IL-10) mutein comprising one or more mutations selected from R27L, K34D, D41G, L46K, Q38E, Q38R, Q38D, K138L, K138D, H14Q, F15Y, M22V, K49T, K49S, F56Y, Y59T, L60Q, Q63E, Q63L, Q70E, Q70K, M77R, M77V, Q79R, Q79C, D84R, A89P, H90E, H90Q, S93E, S93Q, T100R, L103E, H109D, R110P, R110Q, L112V, E115K, A127M, K130Q, I136C, Y137C, M154V, M156C, K157N, of SEQ ID NO:
- 2.
A human interleukin-10 (IL-10) mutein comprising the amino acid sequence of any one of SEQ ID NOs:
- 3-10 or SEQ ID NOS:
- 2138, 2140, 2142, 2144, 2146, 2148, 2150, 2152, 2154, 2156, 2160, 2162, 2164, 2166, 2168, 2170 2172, 2174, 2176, 2178, 2180, 2182, 2360, 2362, 2364, 2368, 2370, 2372, 2374, 2376, 2378, 2380, 2382, 2384, 2386, 2388, 2390, 2392, 2394, 2396, 2398, 2400, 2402, 2404, 2406, 2408, 2410, 2412, 2414, 2416, 2418, 2420, 2422, 2424, 2426, 2428, 2430, 2432, 2434, 2436, 2438, 2440, 2442, 2444, 2446, 2448, 2450, 2452, 2454, 2456, 2458, 2460, 2462, 2464, 2466, 2468, 2470, 2472, 2474, 2476, 2478, 2480, 2482, 2484, 2486, 2488, 2490, 2492, 2494, 2496, 2500, 2502, 2504, 2506, 2508, 2510, 2512, 2514, 2516, 2518, 2520, 2522, 2524, 2526, 2528, 2530, 2532, 2534, 2536, 2540 or 2777-2791.
Dependencies are inferred from the claim text.